BioSpace News Archive

Business

Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates

Galera Therapeutics, Inc. today announced financial results for the fourth quarter and year ended December 31, 2022 and provided recent corporate updates.

March 8, 2023
·
12 min read
Drug Development

Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

Rezolute, Inc. will host a virtual event to highlight the Company’s RZ402 Phase 2 clinical program and the rationale for an oral plasma kallikrein inhibitor (PKI) in diabetic macular edema (DME) on Wednesday, March 22, 2023, from 4:30 p.m.

March 8, 2023
·
5 min read
Biotech Bay

ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata

ASLAN Pharmaceuticals today announced that it will be hosting a virtual research and development day on Thursday, March 16, 2023, from 10:00 am – 11:30 am ET.

March 8, 2023
·
5 min read
Pharm Country

Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab

Tiziana Life Sciences Ltd. today announced a publication in the preeminent1 journal, Proceedings of the National Academy of Sciences (PNAS), that illustrates the immunological basis of the mechanism of action (MoA) for intranasal foralumab.

March 8, 2023
·
4 min read
Deals

Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2023

Zimmer Biomet Holdings, Inc. today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2023.

March 8, 2023
·
1 min read
BioCapital

REGENXBIO to Participate in Upcoming Investor Conferences - March 8, 2023

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences.

March 8, 2023
·
1 min read
Drug Development

Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics today announced the first participant in Italy has been dosed in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

March 8, 2023
·
4 min read
Business

Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates

Minerva Neurosciences, Inc. today reported business updates and financial results for the fourth quarter and year ended December 31, 2022.

March 8, 2023
·
8 min read
Business

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

Biogen Inc . (NASDAQ: BIIB) today announced that the Board of Directors has elected Caroline Dorsa as Chair of the Board of Directors, effective immediately following the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to take place on June 14, 2023.

March 8, 2023
·
7 min read
Vivos Therapeutics to Participate in Fireside Chat at the 35th Annual ROTH Conference

Vivos Therapeutics, Inc. today announced that Kirk Huntsman, Vivos’ Chairman and CEO and Brad Amman, CFO, will participate in a fireside chat at the 35th Annual ROTH Conference on Tuesday, March 14, 2023 at 1:30 pm PT (4:30 pm ET).

March 8, 2023
·
4 min read